RETRACTION: STUB1 Suppresseses Tumorigenesis and Chemoresistance Through Antagonizing YAP1 Signaling

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancer Science Pub Date : 2024-08-29 DOI:10.1111/cas.16307
{"title":"RETRACTION: STUB1 Suppresseses Tumorigenesis and Chemoresistance Through Antagonizing YAP1 Signaling","authors":"","doi":"10.1111/cas.16307","DOIUrl":null,"url":null,"abstract":"<p><b>RETRACTION</b>: D.-E Tang, Y. Dai, L.-W. Lin, Y. Xu, D.-Z. Liu, X.-P. Hong, H.-W. Jiang, and S.-H. Xu, “STUB1 Suppresseses Tumorigenesis and Chemoresistance Through Antagonizing YAP1 Signaling,” <i>Cancer Science</i> 110, no. 10 (2019): 3145–3156, https://doi.org/10.1111/cas.14166.</p><p>The above article, published online on 8 August 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Masanori Hatakeyama; the Japanese Cancer Association; and John Wiley &amp; Sons Australia, Ltd.</p><p>The retraction has been agreed due to concerns raised by third parties on the data presented in the article. Specifically, the article shows results from two unknown/unverifiable cell lines, BSG-823 and BGC-803. The corresponding author acknowledged that both cell lines may correspond to the cell line BGC-823 and stated that a typographical mistake was made by the provider in labeling the samples. However, these cell lines have been used as distinct and independent, raising severe concerns on the overall accuracy of the full body of data; the authors failed to comply to our request to provide raw data. Finally, several cell lines used in this study have been reported as problematic (SGC-7901,<span><sup>1, 2</sup></span> MGC-803,<span><sup>3, 4</sup></span> and MKN-28<span><sup>5</sup></span>). For these reasons, the editors no longer have trust in the reliability of the data and consider the conclusions of this article to be invalid. The authors have been informed of the decision of retraction. Authors Yong Dai and Haowu Jiang state that they did not directly participate in the experiments conducted for the study and were unaware of its submission; they agree with the decision of retraction considering the detected issues. The corresponding author Song-Hui Xu states that all authors have been duly informed of the submission of the article and agrees with the decision of retraction. The remaining co-authors were unavailable for a final confirmation.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 11","pages":"3830"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531953/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16307","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

RETRACTION: D.-E Tang, Y. Dai, L.-W. Lin, Y. Xu, D.-Z. Liu, X.-P. Hong, H.-W. Jiang, and S.-H. Xu, “STUB1 Suppresseses Tumorigenesis and Chemoresistance Through Antagonizing YAP1 Signaling,” Cancer Science 110, no. 10 (2019): 3145–3156, https://doi.org/10.1111/cas.14166.

The above article, published online on 8 August 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Masanori Hatakeyama; the Japanese Cancer Association; and John Wiley & Sons Australia, Ltd.

The retraction has been agreed due to concerns raised by third parties on the data presented in the article. Specifically, the article shows results from two unknown/unverifiable cell lines, BSG-823 and BGC-803. The corresponding author acknowledged that both cell lines may correspond to the cell line BGC-823 and stated that a typographical mistake was made by the provider in labeling the samples. However, these cell lines have been used as distinct and independent, raising severe concerns on the overall accuracy of the full body of data; the authors failed to comply to our request to provide raw data. Finally, several cell lines used in this study have been reported as problematic (SGC-7901,1, 2 MGC-803,3, 4 and MKN-285). For these reasons, the editors no longer have trust in the reliability of the data and consider the conclusions of this article to be invalid. The authors have been informed of the decision of retraction. Authors Yong Dai and Haowu Jiang state that they did not directly participate in the experiments conducted for the study and were unaware of its submission; they agree with the decision of retraction considering the detected issues. The corresponding author Song-Hui Xu states that all authors have been duly informed of the submission of the article and agrees with the decision of retraction. The remaining co-authors were unavailable for a final confirmation.

回归:STUB1 通过拮抗 YAP1 信号抑制肿瘤发生和化疗抗性
返回: D.-E Tang、Y. Dai、L.-W. Lin、Y. Xu、D.-Z.Lin, Y. Xu, D.-Z.Liu, X.-P. Hong, H.-W. Jiang, and S.-H.Jiang, and S.-H. Xu.徐,"STUB1 Suppresses Tumorigenesis and Chemoresistance Through Antagonizing YAP1 Signaling," Cancer Science 110, no:3145-3156, https://doi.org/10.1111/cas.14166.The 上述文章于2019年8月8日在线发表于Wiley Online Library (wileyonlinelibrary.com),经杂志主编Masanori Hatakeyama、日本癌症协会和John Wiley & Sons Australia, Ltd.同意,已被撤回。撤回的原因是第三方对文章中提供的数据提出了担忧。具体来说,文章显示了两个未知/无法验证的细胞系 BSG-823 和 BGC-803 的结果。通讯作者承认这两个细胞系可能与 BGC-823 细胞系相对应,并表示提供者在标注样本时出现了排版错误。然而,这些细胞系一直被当作不同的独立细胞系使用,这让我们对全部数据的整体准确性产生了严重的担忧;作者未能按照我们的要求提供原始数据。最后,本研究中使用的几个细胞系(SGC-7901,1, 2 MGC-803,3, 4 和 MKN-285)已被报道存在问题。由于这些原因,编辑不再相信数据的可靠性,并认为这篇文章的结论无效。撤稿决定已通知作者。作者戴勇和蒋浩武表示,他们没有直接参与该研究的实验,也不知道该研究的提交;考虑到所发现的问题,他们同意撤稿决定。通讯作者徐松辉表示,所有作者都已被正式告知文章的提交情况,并同意撤稿决定。其余共同作者无法进行最终确认。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信